OrbiMed’s VYNE Therapeutics VYNE Stock Holding History

OrbiMed’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,248	Closed	-$1.03M	–	160
2020 Q2	$1.03M	Sell	8,248 -16,076	-66%	-$2.18M	0.01%	133
2020 Q1	$4.69M	Buy	+24,324	New	+$7.63M	0.08%	109
2019 Q4	–	Sell	-9,203	Closed	-$2.97M	–	147
2019 Q3	$2.97M	Sell	9,203 -154	-2%	-$49.7K	0.06%	104
2019 Q2	$4.04M	Buy	9,357 +553	+6%	+$274K	0.06%	115
2019 Q1	$4.98M	Buy	+8,804	New	+$4.23M	0.08%	108
2018 Q4	–	Sell	-6,566	Closed	-$4.66M	–	152
2018 Q3	$4.66M	Buy	+6,566	New	+$4.05M	0.06%	130

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed's VYNE Position: Q3 2020 in Review

OrbiMed sold out of VYNE Therapeutics (VYNE) in Q3 2020, closing a stake of 8,248 shares — an estimated $1.03M sold.

OrbiMed first reported a position in VYNE in Q3 2018 and held it in 6 quarters. The position peaked at $4.98M in Q1 2019. 105 funds tracked by Wall St. Rank hold VYNE as of Q3 2020.

OrbiMed reported no remaining VYNE Therapeutics position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 8,248 VYNE Therapeutics shares in Q3 2020, an estimated $1.03M.
OrbiMed first reported a position in VYNE Therapeutics in Q3 2018 and held it in 6 quarters.
OrbiMed's VYNE Therapeutics position peaked at $4.98M in Q1 2019.
105 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.